Benzinga · Oct 9, 2026
RBC Capital Maintains Sector Perform on Exelixis, Raises Price Target to $51
RBC Capital analyst Leonid Timashev maintains Exelixis (NASDAQ:EXEL) with a Sector Perform and raises the price target from $45 to $51.
EX
NASDAQ · EXEL
Exelixis, Inc.
Healthcare · Biotechnology
$62.83
Down-$0.84 (-1.34%)
Updated Oct 16, 2026, 7:28 PM
SID Score
7.4/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 11.1B
- P/E ratio
- 16.39
- Dividend yield
- 0.00%
- 52-week range
- $33.76 – $61.66
- Volume
- 2.77M
- Avg. volume
- 2.76M
Price performance · EXEL
EXEL price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 15, 2026
EXEL closed at $62.83 after 21 trading sessions, up 7.42% for the selected period.
- Last close
- $62.83
- Period change
- +7.42%
- Period low
- $56.73
- Period high
- $62.83
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | $61.69 | $63.31 | $61.2801 | $62.83 | 2.77M |
| Oct 14, 2026 | $59.92 | $61.175 | $59.56 | $60.99 | 2.75M |
| Oct 13, 2026 | $60.00 | $60.00 | $58.59 | $59.51 | 2.62M |
| Oct 12, 2026 | $60.48 | $61.66 | $59.80 | $59.82 | 3.13M |
| Oct 9, 2026 | $59.00 | $60.83 | $59.00 | $59.86 | 2.67M |
| Oct 8, 2026 | $58.07 | $60.08 | $57.91 | $59.02 | 2.68M |
| Oct 7, 2026 | $58.47 | $59.265 | $57.88 | $58.44 | 2.37M |
| Oct 6, 2026 | $58.85 | $59.00 | $57.02 | $58.33 | 2.03M |
| Oct 5, 2026 | $58.36 | $59.79 | $57.815 | $58.85 | 2.58M |
| Oct 2, 2026 | $58.11 | $58.97 | $57.94 | $58.39 | 1.97M |
| Oct 1, 2026 | $58.54 | $59.28 | $57.76 | $57.94 | 1.37M |
| Sep 30, 2026 | $58.90 | $61.14 | $58.40 | $58.41 | 3.07M |
| Sep 29, 2026 | $58.06 | $59.125 | $57.53 | $58.65 | 2.24M |
| Sep 28, 2026 | $57.97 | $58.66 | $57.51 | $58.37 | 1.28M |
| Sep 25, 2026 | $58.25 | $58.62 | $57.63 | $58.16 | 1.99M |
| Sep 24, 2026 | $56.70 | $57.99 | $56.58 | $57.95 | 1.93M |
| Sep 23, 2026 | $58.22 | $58.66 | $56.26 | $56.73 | 1.43M |
| Sep 22, 2026 | $57.65 | $59.0895 | $57.33 | $58.15 | 1.86M |
| Sep 21, 2026 | $58.61 | $58.805 | $56.9009 | $57.22 | 2.1M |
| Sep 18, 2026 | $58.285 | $59.15 | $57.895 | $58.36 | 5.24M |
| Sep 17, 2026 | $57.23 | $58.52 | $57.23 | $58.49 | 1.79M |
Latest EXEL news
The latest Smart Investors Daily articles mentioning EXEL.
Stock researchCompany · Overview
Company
Market Activity
Research & News
EXEL research
Overview
Company profile and research snapshot.
Company profile
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $43.82
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 9, 2026 | RBC Capital | Sector Perform | — |
| Oct 8, 2026 | RBC Capital | Sector Perform | — |
| Oct 7, 2026 | Truist Securities | Hold | — |
| Aug 19, 2026 | BMO Capital | Market Perform | — |
| Aug 6, 2026 | Truist Securities | Hold | — |
News briefing
No generated briefing is available yet.
Benzinga · Oct 8, 2026
RBC Capital Maintains Sector Perform on Exelixis, Lowers Price Target to $45
RBC Capital analyst Leonid Timashev maintains Exelixis (NASDAQ:EXEL) with a Sector Perform and lowers the price target from $46 to $45.
Yahoo · Oct 8, 2026
Is Exelixis (EXEL) Fully Valued As Its Cabozantinib Patent Window Comes Into Focus?
Exelixis (EXEL) is drawing attention after a year of strong share performance. The stock is up about 51% over the past 12 months and roughly 171% over three years. Recent trading in Exelixis has been relatively steady, with the share price at US$58.44 and short term moves broadly flat. However, the 1 year total shareholder return of 51.24% and 3 year total shareholder return of 171.81% indicate momentum that has built over time rather than faded. Scan other oncology and biotech players...
Yahoo · Oct 8, 2026
Exelixis (EXEL) Stock May Be Undervalued As Earnings Stay In Focus
Exelixis has seen its share price climb over multiple time frames, so the real issue for anyone looking at the stock now is whether that performance is backed up by the earnings power of the business. With the current valuation lens focused squarely on profits, the question is how much of that story is already reflected in today's price. Over the past 5 years, Exelixis has delivered a total return of 172.4%, which puts the spotlight on whether the underlying earnings profile can justify that...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
